摘要
目的 探究小檗碱、黄芪甲苷联用降糖机制.方法 2型糖尿病大鼠模型动物随机分为小檗碱组、黄芪甲苷组及联合用药组,分别灌胃给予小檗碱、黄芪甲苷及小檗碱+黄芪甲苷,2周后进行粪便中肠道菌群16S rRNA测序.结果 联合用药比单独用药更有利于降低血糖和维持体重;同时,联合用药可上调Akkermansia、Parabacteroides菌群丰度、下调Proteobacteria菌群丰度,促进2型糖尿病模型大鼠血糖降低.结论 小檗碱和黄芪甲苷联合用药可通过调节与糖尿病相关肠道菌群的相对丰度而降低模型动物血糖,该研究为揭示不同中药成分间相互作用及配伍机制提供了重要线索.
Objective To explore the hypoglycemic mechanism of berberine combined with astragalosideⅣ.Methods Berberine and astragalosideⅣ,alone or in combination were administrated to type 2 diabetic rats for 2 weeks,and the hypoglycemic effect and 16 S rRNA sequence of gut microbiota in feces were detected.Results The combination of berberine and astragalosideⅣwas more beneficial for lowering blood glucose and maintaining body weight than berberine or astragalosideⅣalone.Meanwhile,the up-regulated abundance of Akkermansia and Parabacteroides and the down-regulated abundance of Proteobacteria were observed in the combined group with the decrease of blood glucose in type 2 diabetic rats.Conclusion The combination of berberine and astragalosideⅣcan exert the hypoglycemic effect through modulating the relative abundance of gut microbiota associated with diabetes,which can provide important basis for revealing the interaction and compatibility mechanism of different TCM components.
作者
孟琦
宝丽
张烨
张蕾
王真真
鄢丹
孟祥乐
MENG Qi;BAO Li;ZHANG Ye;ZHANG Lei;WANG Zhen-zhen;YAN Dan;MENG Xiang-le(College of Pharmacy,Henan University,Kaifeng 475000,China;Bejing Key Laboratory&Joint Laboratory,for International Cooperation of Bio-characteristic Profiling for Evaluation of Clinical Rational Drug Use,Bejing Shjitan Hospital,Capital Medical University,Bejing 100038,China;Department of Pharmacy,the First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China)
出处
《食品与药品》
CAS
2020年第3期169-175,共7页
Food and Drug
基金
国家自然科学基金项目(81773891)
国家“重大新药创制”科技重大专项(2017ZX09301-040)。
关键词
小檗碱
黄芪甲苷
联合用药
肠道菌群
降血糖
berberine
astragalosideⅣ
drug combination
gut microbiota
hypoglycemic effect
